Absorb IV: Bioresorbable Scaffolds with an Optimized Implantation Technique

 Courtesy of the SBHCI.

The Absorb IV trial randomized 2604 patients in a 1:1 ratio to receive an Absorb everolimus-eluting bioresorbable scaffold or a Xience stent.

Absorb IV: la plataforma bioabsorbible con una técnica de implante perfeccionada

With the aim of minimizing the problems observed in previous studies, the Absorb IV protocol excluded small caliber (<2.5 mm) vessels and included mandatory aggressive pre-dilation followed by non-complacent balloon post-dilation. Patients could be randomized only after successful pre-dilation, which prevented the inclusion of patients with lesions that could not be dilated. Furthermore, unlike prior studies, Absorb IV did enroll patients with acute coronary syndrome.


Read also:ABSORB II: No Benefits from Scaffolds After Complete Bioresorption”.


Primary endpoint target lesion failure was present in 5% of patients in the Absorb arm vs. 3.7% of patients in the Xience arm (p = 0.02 for non-inferiority and p = 0.11 for superiority). The rate of ischemia-driven target-vessel revascularization was 1.2% vs. 0.2% (p = 0.003), and the rate of device thrombosis was 0.6% vs. 0.2% (p = 0.6%).

 

Conclusion

A better implantation technique reduced the rate of thrombosis among patients in the Absorb group, although it still is higher than the rate for patients with the Xience stent. The rate of revascularization is also higher for the Absorb arm.

 

 Courtesy of the SBHCI.

 

Original title: 30-Day Outcomes From a Randomized Trial of a Bioresorbable Scaffold vs a Metallic DES in Patients With Coronary Artery Disease.

Presenter: Gregg W. Stone.

 

ABSORB-IV


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

ROUTE TRAIL: DKCRUSH vs. DKRUSH Culotte in Non-Left Main Bifurcation Lesions

Coronary bifurcation lesions represent a frequent technical challenge, making between 15% and 20% of cases. Though provisional stenting is mostly used, complex bifurcations are...

TENDERA: Comparing Conventional vs. Distal Transradial Occlusion for Coronary Interventions

Supported by robust data, favorably compared against the transfemoral, the transradial approach has consolidated as the safest method for percutaneous intervention, particularly in terms...

AHA 2024 | SUMMIT

It has been previously shown that the pharmacological treatment of obesity (semaglutide) can reduce cardiovascular events in patients with cardiac failure (CF) and preserved...

AHA 2024 – BPROAD

Hypertension (elevated blood pressure, BP) is the most common comorbidity among diabetic patients and has been associated with higher cardiovascular risk, though as a...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ROUTE TRAIL: DKCRUSH vs. DKRUSH Culotte in Non-Left Main Bifurcation Lesions

Coronary bifurcation lesions represent a frequent technical challenge, making between 15% and 20% of cases. Though provisional stenting is mostly used, complex bifurcations are...

TENDERA: Comparing Conventional vs. Distal Transradial Occlusion for Coronary Interventions

Supported by robust data, favorably compared against the transfemoral, the transradial approach has consolidated as the safest method for percutaneous intervention, particularly in terms...

Asymptomatic Aortic Stenosis: A Complex Decision

Asymptomatic severe aortic stenosis continues to pose a significant challenge when it comes to clinical decision-making, often due to the difficulty in identifying symptoms....